Aldosterone

AstraZeneca’s Baxdrostat Lowers Blood Pressure in Phase III, Setting Up 2025 Filings

The aldosterone‑synthesis inhibitor cut systolic readings by roughly 9–10 mmHg versus placebo in the BaxHTN trial, prompting plans for regulatory submissions.